Clinically meaningful improvement from 24-week treatment period was maintained for 24 weeks after drisapersen administration ceased Chicago, IL, March 17, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week  data from its […]
CureDuchenne will host our annual Champions to CureDuchenne Newport Beach Gala on Saturday, March 29 at the Balboa Bay Club & Resort. The event will celebrate CureDuchenne’s 10 years of successfully advancing Duchenne research. We’ll honor Doug Freeman, the business leader who helped shape our venture philanthropy model; dine on a delicious meal created by […]
Leiden, February 18th , 2014 Dear Patient Group Representative, We hope this note finds you well. When we last communicated, we announced that Prosensa had regained all rights to drisapersen from GSK and retained the rights to the other DMD programs. Upon the announcement of the transfer of rights, GSK and Prosensa entered into a […]

Prosensa Patient Webinar

Blog, Research
0
Dr. Giles Campion, Prosensa’s Chief Medical Officer (http://www.prosensa.eu/) presented an overview of the latest drisapersen results in this morning’s patient webinar. An analysis of the Phase III data suggests that administering the drug earlier in the disease and treating longer can delay the progression of DMD. For example, in the 96-week extension data from the […]
Dear all, As announced last week, Prosensa will organize a patient focused webinar on Tuesday 21st of January at 8 AM ET / 14hrs CET. Practical details required to dial in for this webinar are provided on the Prosensa website at:  http://ir.prosensa.eu/events.cfm (open additional information by clicking on it). If you have any questions that […]
Leiden,The Netherlands,Jan. 16, 2014(GLOBE NEWSWIRE) –Prosensa Holding N.V.(NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet medical need, today announced initial findings from further analyses from the aggregate data from the clinical development program of drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD). “We are encouraged by […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 15, 2014– Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 120 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results through more than two years showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable […]
Dear Patient Group Representative, We are writing as we would like to share with you that as of January 12, 2014, Prosensa has regained the rights to drisapersen from GSK and retained the rights to the other DMD programs. Prosensa and GSK have issued a press release to announce this news, and I have attached […]
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE   NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK)   today announced that Prosensa has regained all rights from GSK to drisapersen   and will retain rights to all other programs for the treatment of Duchenne   Muscular Dystrophy (DMD). This transfer of rights represents the […]
Help CureDuchenne Now! With only 5 days left in the year, CureDuchenne is doing all it can to raise the dollars needed to fund promising and innovative research to find a cure for Duchenne muscular dystrophy. We have a successful track record of translating promising research into clinical trials, and have funded seven research projects that […]
1 17 18 19 20 21 25

Inspire Others

Have a story to tell that will inspire or a resource to share that would be helpful to the Duchenne community?

CONTRIBUTE

Patient Registry

Enroll here to make sure you’re alerted and aware of the latest pharmaceutical treatments for Duchenne muscular dystrophy that become available as research progresses every day.

REGISTER NOW
REGISTER NOW